Clin Orthop Surg.  2019 Jun;11(2):233-236. 10.4055/cios.2019.11.2.233.

Clinical Outcome of Beta-Tricalcium Phosphate Use for Bone Defects after Operative Treatment of Benign Tumors

• Chung H
• Kim S
• Chung SH

• KMID: 2445060
• DOI: http://doi.org/10.4055/cios.2019.11.2.233

Abstract

BACKGROUND
We investigated the clinical outcome in patients whose cavitary bone defects were treated with beta-tricalcium phosphate (β-TCP) after surgical removal of benign tumors.
METHODS
Between March 2015 and December 2015, 20 patients who underwent operation for bone tumors were enrolled into this study and prospectively followed up for a median period of 28.1 months.
RESULTS
When the radiographic sign of complete resorption was defined as greater than 50% resorption of the allograft material accompanied by bone remodeling until 12 months, 55% of patients had complete resorption. Positive correlation between the filling volume and time needed for complete resorption was not found (p = 0.184).
CONCLUSIONS
Purified β-TCP could be a suitable choice as a bone graft substitute after the removal of benign bone tumors.

Keyword

Beta-tricalcium phosphate; Bone transplantation

Figure

• 

  Fig. 1 Radiographs of a 57-year-old woman with intraosseous lipoma in the proximal radius. The filling volume of beta-tricalcium phosphate (β-TCP) was measured using the following formula: (A × B2) / 2, where A is the smaller diameter measured perpendicular to B, and B is the longest diameter. (A) Lateral view of the radius showing β-TCP injected immediately after surgery. The filling volume was 3.83 cm3. (B) Lateral view of the radius with complete resorption after 12 months. The filling volume was 0.43 cm3.

• 

  Fig. 2 Radiographs of a 57-year-old woman with intraosseous lipoma in the proximal radius. Anteroposterior (A) and lateral (B) views of the radius showing beta-tricalcium phosphate (β-TCP) injected immediately after surgery. Anteroposterior (C) and lateral (D) views of the radius with complete resorption of β-TCP after 12 months. The resorption rate was 88.8%.

• 

  Fig. 3 The graph shows the time taken for complete resorption according to filling volume. Correlation between the filling volume and time needed for complete resorption was not found (p = 0.184).

Reference

1. Arrington ED, Smith WJ, Chambers HG, Bucknell AL, Davino NA. Complications of iliac crest bone graft harvesting. Clin Orthop Relat Res. 1996; (329):300–309.

2. Banwart JC, Asher MA, Hassanein RS. Iliac crest bone graft harvest donor site morbidity: a statistical evaluation. Spine (Phila Pa 1976). 1995; 20(9):1055–1060. PMID: 7631235.

3. Dong J, Uemura T, Shirasaki Y, Tateishi T. Promotion of bone formation using highly pure porous beta-TCP combined with bone marrow-derived osteoprogenitor cells. Biomaterials. 2002; 23(23):4493–4502. PMID: 12322969.

4. Hollinger JO, Brekke J, Gruskin E, Lee D. Role of bone substitutes. Clin Orthop Relat Res. 1996; (324):55–65.

5. Laurencin C, Khan Y, El-Amin SF. Bone graft substitutes. Expert Rev Med Devices. 2006; 3(1):49–57. PMID: 16359252.

6. Bucholz RW. Nonallograft osteoconductive bone graft substitutes. Clin Orthop Relat Res. 2002; (395):44–52. PMID: 11937865.

7. Galois L, Mainard D, Delagoutte JP. Beta-tricalcium phosphate ceramic as a bone substitute in orthopaedic surgery. Int Orthop. 2002; 26(2):109–115. PMID: 12078872.

8. Nicholas RW, Lange TA. Granular tricalcium phosphate grafting of cavitary lesions in human bone. Clin Orthop Relat Res. 1994; (306):197–203.

9. Vaccaro AR. The role of the osteoconductive scaffold in synthetic bone graft. Orthopedics. 2002; 25(5 Suppl):s571–s578. PMID: 12038844.

10. Botez P, Sirbu P, Simion L, Munteanu F, Antoniac I. Application of a biphasic macroporous synthetic bone substitutes CERAFORM®: clinical and histological results. Eur J Orthop Surg Traumatol. 2009; 19(6):387–395.

11. Hirata M, Murata H, Takeshita H, Sakabe T, Tsuji Y, Kubo T. Use of purified beta-tricalcium phosphate for filling defects after curettage of benign bone tumours. Int Orthop. 2006; 30(6):510–513. PMID: 16736145.

12. Mano JF, Sousa RA, Boesel LF, Neves NM, Reis RL. Bioinert, biodegradable and injectable polymeric matrix composites for hard tissue replacement: state of the art and recent developments. Compos Sci Technol. 2004; 64(6):789–817.

13. Naito K, Obayashi O, Mogami A, Itoi A, Kaneko K. Fracture of the calcium phosphate bone cement which used to enchondroma of the hand: a case report. Eur J Orthop Surg Traumatol. 2008; 18(5):405–408.